← Back to Analyst Consensus 
CBIO Buy
CRESCENT BIOPHARMA, INC.
Current Price —
Implied Upside —
Analysts 14
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Next Earnings
Nov 4, 2026 (8 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 19, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Oct 6, 2026 | HC Wainwright & Co. | upgrade | Neutral → Buy | — | 44% |
| Sep 14, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 57% |
| Aug 27, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 57% |
| Jun 1, 2026 | HC Wainwright & Co. | downgrade | Buy → Neutral | — | 44% |
| Mar 2, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Jan 21, 2026 | Guggenheim | initiate | — → Buy | $35 | 52% |
| Aug 27, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $25 | 44% |
| Aug 25, 2025 | Jefferies | initiate | — → Buy | $26 | 52% |
| Aug 11, 2025 | HC Wainwright & Co. | initiate | — → Buy | $25 | 44% |
| Jul 14, 2025 | Wedbush | initiate | — → Outperform | $27 | 57% |
| Jun 25, 2025 | Stifel | initiate | — → Buy | $28 | 54% |
| Jun 18, 2025 | LifeSci Capital | initiate | — → Outperform | $22 | 57% |
Price Target Trend
Apr 21, 2026 Latest: $31.5 Oct 25, 2026
EPS Estimates
+1q $-0.61
Lo: $-0.63 Hi: $-0.57
3 analysts ▲1
0y $-2.35
Lo: $-2.36 Hi: $-2.35
3 analysts ▲1
+1y $-2.63
Lo: $-3.27 Hi: $-1.98
3 analysts 0q $-0.57
Lo: $-0.62 Hi: $-0.53
3 analysts ▲1
Cross-Platform Signals
No cross-platform signals in the last 90 days